|
| |
BioPortfolio's Approved Drugs DatabaseEligardLeuprolide AcetateDownload PDF containing detailed information.
Press Releases About Eligard:
|
 |
| QLT announces third quarter results for 2009 |
27th October, 2009 |
QLT Inc. |
QLT SEPARATELY ANNOUNCES SHARE REPURCHASE PROGRAM
VANCOUVER, Oct. 27 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today reported financial
|
| QLT announces sale of QLT USA, Inc. for up to US$230 million |
1st October, 2009 |
QLT Inc. |
VANCOUVER, Oct. 1 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today announced that it has completed the sale of all of the shares of its
|
| DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology |
8th July, 2009 |
DOR BioPharma, Inc. |
PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that it has received a
|
| QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy |
15th June, 2009 |
QLT Inc. |
VANCOUVER, June 15 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced that twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study were
|
| QLT announces positive results from the evaluation of Visudyne(R) combination therapy |
2nd June, 2009 |
QLT Inc. |
VANCOUVER, June 2 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced positive twelve-month primary analysis results from the Phase II RADICAL study (Reduced Fluence Visudyne
|
Companies working in the area of Eligard from Bioportfolio's Biocorporate database : | |
| Company Name | |
QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical...
www.qltinc.com View full profile
| |
QLT Inc. is a global biopharmaceutical company specializing in developing treatments for eye diseases as well as dermatological and urological conditions.
Together with our subsidiaries, we have...
www.atrixlabs.com/ View full profile
| |
Formed in 1981. Became a public company in 1986. FOUNDERS Founded by a group of University of British Columbia professors, including Dr. Julia Levy who served as the Company's President and CEO from...
www.qltinc.com/ View full profile
| | →View more Eligard related companies. |
This page has been viewed 29 times
Recent Search Terms used to find this page: .
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Eligard across BioPortfolio, or for Eligard Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|
